FDA has approved everolimus (Afinitor, Novartis) tablets to treat patients with progressive neuroendocrine tumors of pancreatic origin that cannot be removed by surgery or that have spread to other parts of the body (metastatic).
FDA has approved everolimus (Afinitor, Novartis) tablets to treat patients with progressive neuroendocrine tumors (NET) of pancreatic origin (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).
Afinitor targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth, and cell metabolism. Preclinical and clinical data have established the role of mTOR in the development and progression of several types of tumors, including advanced PNET.
It is the first new treatment in nearly 3 decades for patients with advanced pancreatic PNET. It is estimated that there are fewer than 1,000 new cases in the United States each year.
The approval was based on phase 3 data from the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial in 410 patients with metastatic or locally advanced disease. The trial showed treatment with Afinitor more than doubled the time without tumor growth (median 4.6 to 11.0 months) and reduced the risk of cancer progression by 65% when compared with placebo in patients with advanced pancreatic NET (HR=0.35; 95% CI, 0.27–0.45; P
“The approval of everolimus marks an important advance for the treatment of pancreatic neuroendocrine tumors,” James C. Yao, MD, associate professor and deputy chair, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, told Formulary. “It is the only approval based on statistically significant and clinically meaningful results from a phase 3 study. Previously available therapies often had limited efficacy or unfavorable toxicity profile. For example, many regional therapy options carried significant risks and required hospitalization. Everolimus targets specific and relevant molecular abnormalities in pancreatic neuroendocrine tumor and presents a novel evidenced-based treatment for this group of patients with unmet medical need.”
In patients treated with Afinitor for neuroendocrine pancreatic tumors, the most commonly reported side effects included inflammation of the mouth (stomatitis), rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.
Afinitor is also approved to treat patients with kidney cancer (advanced renal cell carcinoma), after they fail treatment with Sutent (sunitinib) or Nexavar (sorafenib), and patients with subependymal giant cell astrocytoma (a type of brain cancer) associated with tuberous sclerosis, who cannot be treated by surgery.
Afinitor has another trade name, Zortress, and is approved to treat certain adult patients to prevent organ rejection after a kidney transplant. Zortress has a different safety profile in these patients.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.